Symptomatic Hypertrophic Cardiomyopathy (HCM)
Cardiovascular
2
Pipeline Programs
1
Companies
1
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
CytokineticsAficamten
Clinical Trials (1)
Total enrollment: 900 patients across 1 trials
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Start: May 2021Est. completion: Mar 2028900 patients
Phase 2/3Enrolling By Invitation
Related Jobs in Cardiovascular
Embedded Software and System Test Engineer (H/F)
Cardiawave
Levallois-Perret, France (Hybrid)
Just now
Territory Sales Manager - Iowa / Nebraska
HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr
Director, Medical Affairs
Abbott
Germany - Hesse - Eschborn
Yesterday
Therapy Development Manager
Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday
Associate Regional Clinical Consultant
Johnson & Johnson
Amersfoort, Utrecht, Netherlands
Yesterday
Medical Affairs Sr Scientist- Electrophysiology
Johnson & Johnson
Irvine, California, United States of America
Yesterday
$92K - $148K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space